Literature DB >> 23612190

Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.

Pilar Retamar1, Lorena López-Cerero, Miguel Angel Muniain, Álvaro Pascual, Jesús Rodríguez-Baño.   

Abstract

We investigated the impact of the piperacillin-tazobactam MIC in the outcome of 39 bloodstream infections due to extended-spectrum-β-lactamase-producing Escherichia coli. All 11 patients with urinary tract infections survived, irrespective of the MIC. For other sources, 30-day mortality was lower for isolates with a MIC of ≤ 2 mg/liter than for isolates with a higher MIC (0% versus 41.1%; P = 0.02).

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23612190      PMCID： PMC3697383          DOI： 10.1128/AAC.00135-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  5 in total

1.  Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis.

Authors:  Pilar Retamar; María M Portillo; María Dolores López-Prieto; Fernando Rodríguez-López; Marina de Cueto; María V García; María J Gómez; Alfonso Del Arco; Angel Muñoz; Antonio Sánchez-Porto; Manuel Torres-Tortosa; Andrés Martín-Aspas; Ascensión Arroyo; Carolina García-Figueras; Federico Acosta; Juan E Corzo; Laura León-Ruiz; Trinidad Escobar-Lara; Jesús Rodríguez-Baño
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

2.  Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.

Authors:  Patrick J Gavin; Mira T Suseno; Richard B Thomson; J Michael Gaydos; Carl L Pierson; Diane C Halstead; Jaber Aslanzadeh; Stephen Brecher; Coleman Rotstein; Stephen E Brossette; Lance R Peterson
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 3.  Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern.

Authors:  Johann D D Pitout; Kevin B Laupland
Journal:  Lancet Infect Dis       Date:  2008-03       Impact factor: 25.071

4.  β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.

Authors:  Jesús Rodríguez-Baño; María Dolores Navarro; Pilar Retamar; Encarnación Picón; Álvaro Pascual
Journal:  Clin Infect Dis       Date:  2011-11-04       Impact factor: 9.079

5.  Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation.

Authors:  Christopher R Frei; Nathan P Wiederhold; David S Burgess
Journal:  J Antimicrob Chemother       Date:  2008-02-04       Impact factor: 5.790
  5 in total
  25 in total

1.  Population analysis of Escherichia coli isolates with discordant resistance levels by piperacillin-tazobactam broth microdilution and agar dilution testing.

Authors:  Carole Shubert; Jen Slaughter; David Creely; Alex van Belkum; Jean Pierre Gayral; William Michael Dunne; Gilles Zambardi; Dee Shortridge
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

Review 2.  Impact of borderline minimum inhibitory concentration on the outcome of invasive infections caused by Enterobacteriaceae treated with β-lactams: a systematic review and meta-analysis.

Authors:  E Torres; M Delgado; A Valiente; Á Pascual; J Rodríguez-Baño
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-06-02       Impact factor: 3.267

Review 3.  Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria.

Authors:  Andre Arizpe; Kelly R Reveles; Shrina D Patel; Samuel L Aitken
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

Review 4.  Point-Counterpoint: Piperacillin-Tazobactam Should Be Used To Treat Infections with Extended-Spectrum-Beta-Lactamase-Positive Organisms.

Authors:  Audrey N Schuetz; Sergio Reyes; Pranita D Tamma
Journal:  J Clin Microbiol       Date:  2018-02-22       Impact factor: 5.948

Review 5.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

6.  Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases.

Authors:  Ghady Haidar; Cornelius J Clancy; Ryan K Shields; Binghua Hao; Shaoji Cheng; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

7.  A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.

Authors:  Belén Gutiérrez-Gutiérrez; Salvador Pérez-Galera; Elena Salamanca; Marina de Cueto; Esther Calbo; Benito Almirante; Pierluigi Viale; Antonio Oliver; Vicente Pintado; Oriol Gasch; Luis Martínez-Martínez; Johann Pitout; Murat Akova; Carmen Peña; José Molina; Alicia Hernández; Mario Venditti; Nuria Prim; Julia Origüen; German Bou; Evelina Tacconelli; Mario Tumbarello; Axel Hamprecht; Helen Giamarellou; Manel Almela; Federico Pérez; Mitchell J Schwaber; Joaquín Bermejo; Warren Lowman; Po-Ren Hsueh; Marta Mora-Rillo; Clara Natera; Maria Souli; Robert A Bonomo; Yehuda Carmeli; David L Paterson; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

Review 8.  Bacterial sepsis : Diagnostics and calculated antibiotic therapy.

Authors:  D C Richter; A Heininger; T Brenner; M Hochreiter; M Bernhard; J Briegel; S Dubler; B Grabein; A Hecker; W A Kruger; K Mayer; M W Pletz; D Storzinger; N Pinder; T Hoppe-Tichy; S Weiterer; S Zimmermann; A Brinkmann; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2019-02       Impact factor: 1.041

Review 9.  [Bacterial sepsis : Diagnostics and calculated antibiotic therapy].

Authors:  D C Richter; A Heininger; T Brenner; M Hochreiter; M Bernhard; J Briegel; S Dubler; B Grabein; A Hecker; W A Krüger; K Mayer; M W Pletz; D Störzinger; N Pinder; T Hoppe-Tichy; S Weiterer; S Zimmermann; A Brinkmann; M A Weigand; Christoph Lichtenstern
Journal:  Anaesthesist       Date:  2017-10       Impact factor: 1.041

Review 10.  Beyond Susceptible and Resistant, Part II: Treatment of Infections Due to Gram-Negative Organisms Producing Extended-Spectrum β-Lactamases.

Authors:  Jennifer Curello; Conan MacDougall
Journal:  J Pediatr Pharmacol Ther       Date:  2014-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.